Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ) has announced the launch of the XPressMAX™ Cell-Free Protein Synthesis Kit (Cat#: CFKIT02), a solution designed to accelerate AI-driven high-throughput screening for antibody drug discovery. The kit leverages advanced cell-free protein synthesis technology to produce target proteins and antibodies rapidly in vitro, bypassing the limitations of traditional cell-based expression systems.
According to the company, the XPressMAX™ kit is based on an E. coli lysate fully supplemented with essential transcription and translation components, enabling direct protein synthesis from plasmid or PCR templates. It is specifically optimized for antibody drug discovery, supporting rapid expression and validation of VHH, scFv, Fab, and miniproteins. The kit can complete synthesis in just three hours, with a success rate exceeding 99% and the ability to support complex disulfide bonding for native folding and bioactivity without additional enhancers.
Sino Biological has established a high-throughput cell-free expression platform using XPressMAX™ that validates over 2,000 scFv/VHH molecules in three to four weeks, matching the rapid iteration pace of AI. “Our XPressMAX™ is a significant advancement in research tools and reagents for next-generation therapeutic discovery,” said Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc. “By combining rapid, reliable protein expression with intelligent screening, we are helping our partners compress antibody discovery timelines without compromising quality.”
Dr. Jie Zhang, Sino Biological’s General Manager, added, “AI is revolutionizing antibody screening, but it demands expression systems that can match its speed and throughput. XPressMAX™ achieves rapid, high-success expression of challenging proteins in as little as 3 hours.”
The launch addresses a critical bottleneck in AI-powered drug discovery: the need for rapid experimental validation of computationally designed antibodies. Traditional cell-based protein expression can take days to weeks, slowing the iterative cycle between AI predictions and wet-lab testing. XPressMAX™ reduces this to hours, enabling researchers to test thousands of candidates in parallel and feed results back into AI models for optimization.
Researchers can explore more about XPressMAX™ at Sino Biological's product page or request a free sample via the company's sample request form. Additional information about Sino Biological's cell-free solutions is available on their cell-free protein synthesis page.
